Ability Biologics Gains $18M From Funding Extension Round

The $18 million initial investment extended round for Ability Biologics, a biotech company focused on cancer, has closed.

After a $12 million initial funding round concluded, Ability came out of stealth and launched its Abileap system in December 2023.

The Canadian firm is developing targeted antibody therapies for immune-related illnesses and cancer using Abileap, a generative AI based medicinal research platform.

Ability asserts that one of the biggest collections of antibody-antigen interactions ever created serves as the foundation for their AI technology. This enables it to produce completely human antibodies that may focus on certain tissues and cells in accordance with the local microenvironment, accounting for elements like pH, temperature, the presence of particular metabolites, and secondary antigens.